USP <788> Particulate Matter in Injections

For large-volume parenterals (>100 mL like infusion bags), the limit is not more than 25 particles ≥10 μm and 3 particles ≥25 μm per mL.

If a product’s particulate counts is below these thresholds, it passes the USP <788> test (Method 1, light obscuration). If it fails or if the solution is not suitable for light obscuration (e.g. opaque or viscous samples), a microscopic counting method (Method 2) with even tighter limits (roughly half the above counts) is applied as a confirmatory test. By adopting these limits, USP <788> ensures that every batch of injectable product is carefully tested and verified to be virtually free of harmful particulate contamination before release.

Global Harmonization: Major pharmacopeias and regulators worldwide align with the USP <788> standard. The European Pharmacopeia (Ph. Eur. 2.9.19) and the Japanese Pharmacopeia (JP 6.07) have essentially identical methods and limits for particulate matter in injections. In fact, an ICH guidance has declared USP <788>, Ph. Eur. 2.9.19, and JP 6.07 interchangeable across regions, meaning compliance with one is accepted by authorities in the US, EU, and Japan. For manufacturers, this harmonization simplifies global distribution – a product tested and meeting USP <788> criteria will generally satisfy EU and Japanese requirements as well. (Notably, JP’s limit at exactly the 100 mL volume is slightly more stringent, but regulators have largely agreed on mutual acceptance of the standards.) Other regulatory agencies, from FDA and EMA to Health Canada and others, all expect injectable drugs to meet these compendial particulate matter limits as part of Good Manufacturing Practice. Adhering to USP <788> is thus a key component of Quality Assurance (QA) for any parenteral product, ensuring compliance during audits and safeguarding patient well-being.